{"id":48195,"date":"2022-09-09T23:02:01","date_gmt":"2022-09-09T21:02:01","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/antibe-announces-results-of-2022-annual-meeting\/"},"modified":"2022-09-09T23:02:01","modified_gmt":"2022-09-09T21:02:01","slug":"antibe-announces-results-of-2022-annual-meeting","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/antibe-announces-results-of-2022-annual-meeting\/","title":{"rendered":"Antibe Announces Results of 2022 Annual Meeting"},"content":{"rendered":"
\n

TORONTO–(BUSINESS WIRE)–$ATBPF<\/a>–Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies that target inflammation, is pleased to announce the results of its annual meeting of shareholders (the \u201cMeeting\u201d) held earlier today. All resolutions outlined in the management information circular were approved. Detailed results for the election of directors are provided below:\n<\/p>\n

<\/a><\/p>\n\n\n\n\n\n\n\n\n\n\n
\n

\nDirector Nominee\n<\/p>\n<\/td>\n

\n

\nOutcome\n<\/p>\n<\/td>\n

\n

\n% For\n<\/p>\n<\/td>\n

\n

\n% Withheld\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n

\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nRobert E. Hoffman\n<\/p>\n<\/td>\n

\n

\nElected\n<\/p>\n<\/td>\n

\n

\n89.12%\n<\/p>\n<\/td>\n

\n

\n10.88%\n<\/p>\n<\/td>\n

\u00a0<\/td>\n<\/tr>\n
\n

\nRoderick Flower\n<\/p>\n<\/td>\n

\n

\nElected\n<\/p>\n<\/td>\n

\n

\n94.91%\n<\/p>\n<\/td>\n

\n

\n5.09%\n<\/p>\n<\/td>\n

\u00a0<\/td>\n<\/tr>\n
\n

\nAmal Khouri\n<\/p>\n<\/td>\n

\n

\nElected\n<\/p>\n<\/td>\n

\n

\n93.51%\n<\/p>\n<\/td>\n

\n

\n6.49%\n<\/p>\n<\/td>\n

\u00a0<\/td>\n<\/tr>\n
\n

\nDan Legault\n<\/p>\n<\/td>\n

\n

\nElected\n<\/p>\n<\/td>\n

\n

\n90.14%\n<\/p>\n<\/td>\n

\n

\n9.86%\n<\/p>\n<\/td>\n

\u00a0<\/td>\n<\/tr>\n
\n

\nWalt Macnee\n<\/p>\n<\/td>\n

\n

\nElected\n<\/p>\n<\/td>\n

\n

\n93.91%\n<\/p>\n<\/td>\n

\n

\n6.09%\n<\/p>\n<\/td>\n

\u00a0<\/td>\n<\/tr>\n
\n

\nJennifer McNealey\n<\/p>\n<\/td>\n

\n

\nElected\n<\/p>\n<\/td>\n

\n

\n93.67%\n<\/p>\n<\/td>\n

\n

\n6.33%\n<\/p>\n<\/td>\n

\u00a0<\/td>\n<\/tr>\n
\n

\nJohn L. Wallace\n<\/p>\n<\/td>\n

\n

\nElected\n<\/p>\n<\/td>\n

\n

\n94.31%\n<\/p>\n<\/td>\n

\n

\n5.69%\n<\/p>\n<\/td>\n

\u00a0<\/td>\n<\/tr>\n
\n

\nYung Wu\n<\/p>\n<\/td>\n

\n

\nElected\n<\/p>\n<\/td>\n

\n

\n94.22%\n<\/p>\n<\/td>\n

\n

\n5.78%\n<\/p>\n<\/td>\n

\u00a0<\/td>\n<\/tr>\n<\/table>\n

\nVoting results on all matters voted on at the Meeting have been filed on SEDAR.\n<\/p>\n

\nAbout Antibe Therapeutics Inc.
\n
<\/b>Antibe is a clinical stage biotechnology company leveraging its proprietary hydrogen sulfide platform to develop next-generation safer therapies to target inflammation arising from a wide range of medical conditions. The Company\u2019s current pipeline includes assets that seek to overcome the gastrointestinal (\u201cGI\u201d) ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (\u201cNSAIDs\u201d). Antibe\u2019s lead drug, otenaproxesul, is in clinical development as a safer alternative to opioids and today\u2019s NSAIDs for acute pain. Antibe\u2019s second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company\u2019s anticipated next target is inflammatory bowel disease (\u201cIBD\u201d), a condition long in need of safer, more effective therapies. Learn more at antibethera.com<\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nAntibe Therapeutics Inc.
\n
Christina Cameron
\n
VP Investor Relations
\n
+1 416-577-1443
\n
christina@antibethera.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

TORONTO–(BUSINESS WIRE)–$ATBPF–Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies that target inflammation, is pleased to announce the results of its annual meeting of shareholders (the \u201cMeeting\u201d) held earlier today. All resolutions outlined in the management information circular were approved. Detailed results for the … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-48195","6":"format-standard","7":"category-industry"},"yoast_head":"\nAntibe Announces Results of 2022 Annual Meeting - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/antibe-announces-results-of-2022-annual-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Antibe Announces Results of 2022 Annual Meeting - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"TORONTO–(BUSINESS WIRE)–$ATBPF–Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies that target inflammation, is pleased to announce the results of its annual meeting of shareholders (the \u201cMeeting\u201d) held earlier today. All resolutions outlined in the management information circular were approved. Detailed results for the ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/antibe-announces-results-of-2022-annual-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-09-09T21:02:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220909005529\/en\/718346\/21\/ANTIBE-logo-RGB.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/antibe-announces-results-of-2022-annual-meeting\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/antibe-announces-results-of-2022-annual-meeting\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Antibe Announces Results of 2022 Annual Meeting\",\"datePublished\":\"2022-09-09T21:02:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/antibe-announces-results-of-2022-annual-meeting\\\/\"},\"wordCount\":248,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/antibe-announces-results-of-2022-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220909005529\\\/en\\\/718346\\\/21\\\/ANTIBE-logo-RGB.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/antibe-announces-results-of-2022-annual-meeting\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/antibe-announces-results-of-2022-annual-meeting\\\/\",\"name\":\"Antibe Announces Results of 2022 Annual Meeting - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/antibe-announces-results-of-2022-annual-meeting\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/antibe-announces-results-of-2022-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220909005529\\\/en\\\/718346\\\/21\\\/ANTIBE-logo-RGB.jpg\",\"datePublished\":\"2022-09-09T21:02:01+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/antibe-announces-results-of-2022-annual-meeting\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/antibe-announces-results-of-2022-annual-meeting\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/antibe-announces-results-of-2022-annual-meeting\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220909005529\\\/en\\\/718346\\\/21\\\/ANTIBE-logo-RGB.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220909005529\\\/en\\\/718346\\\/21\\\/ANTIBE-logo-RGB.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/antibe-announces-results-of-2022-annual-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Antibe Announces Results of 2022 Annual Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Antibe Announces Results of 2022 Annual Meeting - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/antibe-announces-results-of-2022-annual-meeting\/","og_locale":"en_US","og_type":"article","og_title":"Antibe Announces Results of 2022 Annual Meeting - Pharma Trend","og_description":"TORONTO–(BUSINESS WIRE)–$ATBPF–Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies that target inflammation, is pleased to announce the results of its annual meeting of shareholders (the \u201cMeeting\u201d) held earlier today. All resolutions outlined in the management information circular were approved. Detailed results for the ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/antibe-announces-results-of-2022-annual-meeting\/","og_site_name":"Pharma Trend","article_published_time":"2022-09-09T21:02:01+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220909005529\/en\/718346\/21\/ANTIBE-logo-RGB.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/antibe-announces-results-of-2022-annual-meeting\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/antibe-announces-results-of-2022-annual-meeting\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Antibe Announces Results of 2022 Annual Meeting","datePublished":"2022-09-09T21:02:01+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/antibe-announces-results-of-2022-annual-meeting\/"},"wordCount":248,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/antibe-announces-results-of-2022-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220909005529\/en\/718346\/21\/ANTIBE-logo-RGB.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/antibe-announces-results-of-2022-annual-meeting\/","url":"https:\/\/pharma-trend.com\/en\/antibe-announces-results-of-2022-annual-meeting\/","name":"Antibe Announces Results of 2022 Annual Meeting - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/antibe-announces-results-of-2022-annual-meeting\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/antibe-announces-results-of-2022-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220909005529\/en\/718346\/21\/ANTIBE-logo-RGB.jpg","datePublished":"2022-09-09T21:02:01+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/antibe-announces-results-of-2022-annual-meeting\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/antibe-announces-results-of-2022-annual-meeting\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/antibe-announces-results-of-2022-annual-meeting\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220909005529\/en\/718346\/21\/ANTIBE-logo-RGB.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220909005529\/en\/718346\/21\/ANTIBE-logo-RGB.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/antibe-announces-results-of-2022-annual-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Antibe Announces Results of 2022 Annual Meeting"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/48195","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=48195"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/48195\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=48195"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=48195"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=48195"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}